Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium

The hypomethylating agents (HMAs) azacitidine and decitabine are most commonly used to treat patients with higher‐risk myelodysplastic syndromes (MDS). To the authors' knowledge, the prognosis of patients with low‐risk and intermediate‐1–risk MDS by the International Prognostic Scoring System (IPSS) after HMA failure has not been explored comprehensively.

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  J. Lancet,et al.  Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. , 2013, Clinical lymphoma, myeloma & leukemia.

[3]  P. Fenaux,et al.  Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure , 2013, Haematologica.

[4]  A. Stamatoullas,et al.  Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents , 2013, Leukemia.

[5]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[6]  B. Esterni,et al.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Benjamin L Ebert,et al.  Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Alan Agresti,et al.  Categorical Data Analysis , 2003 .

[9]  J. Issa,et al.  Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy , 2010, Cancer.

[10]  J. Sierra,et al.  Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. , 2010, Blood.

[11]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[12]  J. Issa,et al.  Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System , 2008, Cancer.

[13]  J. Issa,et al.  Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine , 2008, Leukemia & lymphoma.

[14]  H. Kantarjian,et al.  A prognostic score for patients with lower risk myelodysplastic syndrome , 2008, Leukemia.

[15]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[16]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[17]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[18]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[20]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[21]  D.,et al.  Regression Models and Life-Tables , 2022 .